Hin Sang Group (International) Holding Co. Ltd. has released its Annual Report for the year 2024/2025. The report highlights the company's continued focus on the marketing, selling, and manufacturing of healthcare products, primarily targeting children under the reputable "Hin Sang" brand. During the year, the Group maintained a strong market position in the children's healthcare sector by leveraging its core strengths and competitive advantages. There were no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures reported. The company has not outlined any specific plans for material investments or capital assets as of March 31, 2025. The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.